Paolo Tarantino, Advanced research fellow at Dana-Farber Cancer Institute, posted on X about recent paper by him and Tess O’Meara, Hematology/Oncology Fellow at Dana-Farber Cancer Institute, published in Journal of Clinical Oncology:

“1st line treatment for HER2+ mBC, unchanged for >10 years, is finally evolving. EMERALD introduced 1st line eribulin. PATINA introduced palbo. DB09 may soon introduce T-DXd.

In this editorial, Tess O’Meara and I review this evolution and provide suggestions for Rx tailoring.”

“Lessons From Taxanes Versus Eribulin for First-Line Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the EMERALD Study”

Authors: Paolo Tarantino and Tess O’Meara

Paolo Tarantino: Taxanes vs Eribulin for First-Line Metastatic HER2+ Breast Cancer

More posts featuring Paolo Tarantino.